Sector Category: Life Sciences
Ventyx Biosciences
Developing selective inhibitors of TYK2 for autoimmune diseases.
Read More
NorthSea Therapeutics
Focused on the development of first-in-class therapeutics for NASH and other metabolic, inflammatory and fibrotic diseases.
Read More
Seahorse Bioscience
Acquired by Agilent Technologies. Developer of tools for measuring cell metabolism.
Read More
FlowCardia
Acquired by C.R. Bard. Developer of endovascular devices for the treatment of coronary and peripheral CTO.
Read More
Conor Medsystems
Acquired by Johnson & Johnson. Focused on the development of drug-eluting stents to treat coronary artery disease.
Read More
Akarna Therapeutics
Acquired by Allergan. Focused on the development of a small molecule therapy for the treatment of NASH.
Read More
Vascular Therapies
Focused on the development of a drug-based solution to reduce the failure rate of AV Fistulas in dialysis patients.
Read More